CNBG Unit Soars in Wake of Covid-19 Therapy Made From Survivors' Blood Plasma - (Yicai Global via NewsPoints Desk)

  • A team of scientists at a unit of China National Biotech Group (CNBG) has developed a potential treatment for COVID-19 infection using blood plasma taken from convalescents, reported Yicai Global.

  • Beijing Tiantan Biological Products, which controls Wuhan Blood Products, one of the main collaborators on the project, closed 10% higher on the news.

  • The new therapy has had "markedly good results" in the treatment of over 10 critically ill patients, CNBG said.

  • Within 12 to 24 hours of treatment, inflammation levels dropped, lymphocyte count rose and symptoms were alleviated, the Beijing-based firm added.

  • China's National Health Commission supported the use of convalescent plasma therapy in a document released on February 5, while authorities in Wuhan, the city at the epicenter of the outbreak, are calling on recovered patients to donate their plasma.

  • CNBG has been collecting plasma from convalescent patients in Wuhan since January 20, the news source said.

To read more NewsPoints articles, click here.